2009-07-15 05:03:02 -

Research and Markets ( www.researchandmarkets.com/research/781584/pharmaceutical_pri : ) has announced the addition of Decision Resources, Inc.'s new report " Pharmaceutical Pricing and Reimbursement in China : " to their offering.

With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third largest in the world in 2011. A radical healthcare reform package recently unveiled by the government will more than double public healthcare expenditures from 2009 to 2011.

For biopharmaceutical companies competing in China, future success will depend on a clear understanding of the implications of these reforms.

Questions Answered in This Report



- More than 1 billion of China's 1.3 billion residents now have some form of government-sponsored health insurance. Which are

the most important public health insurance programs? What level of benefits do these programs offer? What changes are planned for the near future?
- Prices for international branded drugs in China are generally comparable to prices in some European markets. How do Chinese prices compare with prices in the United States? Which kinds of drugs have prices close to, or higher than, U.S. prices?
- Hospitals are the dominant distribution channel for prescription drugs in China. Why do hospitals play such an important role in the healthcare system and the pharmaceutical market? How does the government plan to exercise stricter control over hospital prescribing in the future?
- In the future, a drug's reimbursement prospects are likely to depend heavily on inclusion in a new national essential medicines list. How extensive is this list likely to be? How will the healthcare system procure and use drugs on this list?


Scope



- Regulatory structure: key policy decision makers in the Chinese healthcare system.


- Organization and funding of the healthcare system: historical perspective, health insurance, organization of healthcare provision.


- Pharmaceutical pricing: historical pricing procedures, standard pricing procedures, premium pricing, centralized drug tenders, international price comparison.


- Reimbursement and cost containment: drug reimbursement, price cuts.


- Outlook and implications for the pharmaceutical industry: changes to the health insurance system, investment in healthcare facilities and professionals, improved quality and range of healthcare services for patients, new system of hospital funding, overhaul of the pharmaceutical supply system, challenges and opportunities for drug manufacturers.



Key Topics Covered:

Executive Summary


Introduction


Regulatory Structure


Organization and Funding of the Healthcare System


Pharmaceutical Market Trends


Pharmaceutical Pricing


Reimbursement and Cost Containment


Intellectual Property Protection


Outlook and Implications for the Pharmaceutical Industry


Products covered.

- Anastrazole
- Atazanavir
- Bicalutamide
- Bortezomib
- Capecitabine
- Celecoxib
- Cetuximab
- Diclofenac
- Docetaxel
- Erlotinib
- Filgrastim
- Gemcitabine
- Infliximab
- Interferon-beta-1a (Rebif)
- Letrozole
- Leuprolide
- Lopinavir plus ritonavir
- Meloxicam
- Mycophenolate mofetil
- Oseltamivir
- Oxaliplatin
- Peg-interferon alpha 2a
- Peg-interferon alpha 2b
- Pemetrexed
- Pioglitazone
- Rituximab
- Rosiglitazone
- Sorafenib
- Sunitinib
- Tacrolimus
- Temozolomide
- Trastuzumab


For more information visit www.researchandmarkets.com/research/781584/pharmaceutical_pri :

Laura WoodSenior Manager press@researchandmarkets.com : mailto:press@researchandmarkets.com Fax

from USA: 646-607-1907Fax from rest of the world: +353-1-481-1716